There Is A Reason Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd's (SZSE:002864) Price Is Undemanding

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd's (SZSE:002864) price-to-earnings (or "P/E") ratio of 23.5x might make it look like a buy right now compared to the market in China, where around half of the companies have P/E ratios above 30x and even P/E's above 58x are quite common. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/E.

For instance, Shaanxi Panlong Pharmaceutical Group Limited By Share's receding earnings in recent times would have to be some food for thought. One possibility is that the P/E is low because investors think the company won't do enough to avoid underperforming the broader market in the near future. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.

View our latest analysis for Shaanxi Panlong Pharmaceutical Group Limited By Share

Want the full picture on earnings, revenue and cash flow for the company? Then our free report on Shaanxi Panlong Pharmaceutical Group Limited By Share will help you shine a light on its historical performance.

How Is Shaanxi Panlong Pharmaceutical Group Limited By Share's Growth Trending?

The only time you'd be truly comfortable seeing a P/E as low as Shaanxi Panlong Pharmaceutical Group Limited By Share's is when the company's growth is on track to lag the market.

Taking a look back first, the company's earnings per share growth last year wasn't something to get excited about as it posted a disappointing decline of 7.8%. That put a dampener on the good run it was having over the longer-term as its three-year EPS growth is still a noteworthy 6.0% in total. So we can start by confirming that the company has generally done a good job of growing earnings over that time, even though it had some hiccups along the way.

Comparing that to the market, which is predicted to deliver 36% growth in the next 12 months, the company's momentum is weaker based on recent medium-term annualised earnings results.

With this information, we can see why Shaanxi Panlong Pharmaceutical Group Limited By Share is trading at a P/E lower than the market. It seems most investors are expecting to see the recent limited growth rates continue into the future and are only willing to pay a reduced amount for the stock.

The Key Takeaway

Using the price-to-earnings ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.

As we suspected, our examination of Shaanxi Panlong Pharmaceutical Group Limited By Share revealed its three-year earnings trends are contributing to its low P/E, given they look worse than current market expectations. Right now shareholders are accepting the low P/E as they concede future earnings probably won't provide any pleasant surprises. If recent medium-term earnings trends continue, it's hard to see the share price rising strongly in the near future under these circumstances.

And what about other risks? Every company has them, and we've spotted 2 warning signs for Shaanxi Panlong Pharmaceutical Group Limited By Share you should know about.

If these risks are making you reconsider your opinion on Shaanxi Panlong Pharmaceutical Group Limited By Share, explore our interactive list of high quality stocks to get an idea of what else is out there.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.